DNLI as reported
Denali Therapeutics Inc. reported $0 of revenue over the trailing twelve months. 9 reported series are charted on this page, each one as filed.
$0
Revenue, trailing twelve months · to Q3 2024 · every figure below is as filed, with no scoring applied
- Net Income
- −$511M
Net Income · +6.8% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$440M
Free Cash Flow · +20% year on year · trailing twelve months to Q2 2026
- EPS
- −$2.84
EPS · +1.1% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $0 | n/a | Q3 2024 · 7 quarters behind |
| Net Income | −$511M | +6.8% | Q2 2026 |
| EPS | −$2.84 | +1.1% | Q2 2026 |
| Op Margin | −2573% | n/a | Q3 2023 · 11 quarters behind |
| Net Margin | −2263% | n/a | Q3 2023 · 11 quarters behind |
| ROE | −55% | n/a | Q2 2026 |
| ROA | −44% | n/a | Q2 2026 |
| Free Cash Flow | −$440M | +20% | Q2 2026 |
| P/E | 111 | n/a | Q3 2021 · 19 quarters behind |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Denali Therapeutics Inc. (DNLI) - Revenue & ProfitRevenue & ProfitDenali Therapeutics Inc. (DNLI)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com